Kairos Pharma, Ltd. (KAPA) — Dilution Risk Analysis
Current Snapshot
Kairos Pharma, Ltd. (KAPA) has a DilutionWatch score of 57/10 and is classified as HIGH risk. The score date in the source data is 2026-10-03T03:45:52.527348.
This page is assembled from sourced share-structure, market-data, SEC-filing, and DilutionWatch fields. Missing values are left blank rather than estimated.
Dilution Risk Score
Score: 57/10 Source (as of 2026-10-03T03:45:52.527348)
Recent SEC Filings
2 shelf registration or ATM offering filings detected in recent history.
Recent filing forms in the source payload: 424B3 2, 8-K 1, EFFECT 1, XBRL 2.
| Form | Filed | Accession |
|---|---|---|
| 424B3 | 2026-04-01 | 0001493152-26-014691 |
| 424B3 | 2026-04-01 | 0001493152-26-014692 |
| 8-K | 2026-03-02 | 0001493152-26-008435 |
| EFFECT | 2026-01-23 | 9999999995-26-000284 |
| xbrl | 2024-12-31 | xbrl-6795-xbrl_convertible |
| xbrl | 2024-12-31 | xbrl-6795-xbrl_warrant |
Dilution Risk Drivers
| Driver | Stored Value | Source |
|---|---|---|
| ATM offering capacity remaining | $15,000,000 | Source |
| Cash runway | 9 months | Source |
| Three-year share count growth | 66.73% | Source |
DilutionWatch Analysis
- Risk Level
- HIGH (Score: 57/10) Source
- Cash Runway
- 9 months Source
- ATM Offering Capacity Remaining
- $15,000,000 Source
- Share Count Growth (3-Year)
- 66.73% Source
What This Page Does Not Estimate
DilutionWatch does not infer missing cash runway, authorized share count, ATM capacity, shelf capacity, or share-growth values on this page. A blank field means the current source payload did not provide a usable value with provenance.
Scores and classifications are shown only when supplied by the DilutionWatch data layer. SEC filing rows link to their source accession when a filing URL is available.